{"transactions":[{"id":726299,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":726298,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":117.94,"value":1061460.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":726297,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T20:10:30.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":16.54,"value":148860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-077761","document":"tm2618679-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926077761/tm2618679-1_4seq1.xml","form_type":"4"}},{"id":737482,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:15:23.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":4.7,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001553338-26-000001","document":"form4-06152026_040615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000155333826000001/form4-06152026_040615.xml","form_type":"4"}},{"id":741483,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":9000,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741482,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741481,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":107.68,"value":969120.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $107.02 to $108.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741480,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":16.54,"value":99240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":741479,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T23:06:39.000Z","date":"2026-06-10","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":11.8,"value":35400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":10825,"source":{"system":"sec-edgar","filing":"0001104659-26-073049","document":"tm2617708-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926073049/tm2617708-1_4seq1.xml","form_type":"4"}},{"id":756904,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":3000,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":756903,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":9000,"price":99.64,"value":896760.0,"ownership":{"direct":true},"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":756902,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-01T22:31:22.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":true,"shares":9000,"price":11.8,"value":106200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026."}],"balance_after":16825,"source":{"system":"sec-edgar","filing":"0001104659-26-069047","document":"tm2616565-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926069047/tm2616565-1_4seq1.xml","form_type":"4"}},{"id":915903,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.31,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":915902,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":83.68,"value":1673600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.65 to $83.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":915901,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-06T21:38:54.000Z","date":"2026-02-06","kind":"exercise","planned":false,"acquired":true,"shares":20000,"price":8.31,"value":166200.0,"ownership":{"direct":true},"balance_after":27825,"source":{"system":"sec-edgar","filing":"0001104659-26-011575","document":"tm265544-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926011575/tm265544-1_4seq1.xml","form_type":"4"}},{"id":946157,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T00:42:49.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":3762,"derivative":{"exercise_price":87.18,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":3762},"source":{"system":"sec-edgar","filing":"0001104659-26-001478","document":"tm262304-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001478/tm262304-7_4seq1.xml","form_type":"4"}},{"id":946156,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T00:42:49.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":7825,"source":{"system":"sec-edgar","filing":"0001104659-26-001478","document":"tm262304-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926001478/tm262304-7_4seq1.xml","form_type":"4"}},{"id":960288,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":500,"price":68.53,"value":34265.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":56563,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":960287,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":5451,"price":68.01,"value":370722.51,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":57063,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":960286,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-23T23:01:44.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":2416,"price":66.66,"value":161050.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions."}],"balance_after":62514,"source":{"system":"sec-edgar","filing":"0001553338-25-000005","document":"wk-form4_1766530901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000005/wk-form4_1766530901.xml","form_type":"4"}},{"id":963706,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-18T23:35:35.000Z","date":"2025-12-16","kind":"grant","planned":false,"acquired":true,"shares":7819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date."}],"balance_after":64930,"source":{"system":"sec-edgar","filing":"0001553338-25-000003","document":"wk-form4_1766100932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000155333825000003/wk-form4_1766100932.xml","form_type":"4"}},{"id":1019174,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-10-14T20:01:11.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-25-099252","document":"tm2528674-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925099252/tm2528674-1_4seq1.xml","form_type":"4"}},{"id":1019173,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:11.000Z","date":"2025-10-10","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":87.81,"value":702480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $86.71 to $88.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":5130,"source":{"system":"sec-edgar","filing":"0001104659-25-099252","document":"tm2528674-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925099252/tm2528674-1_4seq1.xml","form_type":"4"}},{"id":1019172,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:11.000Z","date":"2025-10-10","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":69.25,"value":277000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":13130,"source":{"system":"sec-edgar","filing":"0001104659-25-099252","document":"tm2528674-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925099252/tm2528674-1_4seq1.xml","form_type":"4"}},{"id":1019171,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T20:01:11.000Z","date":"2025-10-10","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":6.98,"value":83760.0,"ownership":{"direct":true},"balance_after":17130,"source":{"system":"sec-edgar","filing":"0001104659-25-099252","document":"tm2528674-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925099252/tm2528674-1_4seq1.xml","form_type":"4"}},{"id":1032941,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-25T00:35:42.000Z","date":"2025-09-22","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":64.25,"value":257000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":5130,"source":{"system":"sec-edgar","filing":"0001104659-25-093046","document":"tm2526819-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925093046/tm2526819-1_4seq1.xml","form_type":"4"}},{"id":1052786,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-29T21:30:16.000Z","date":"2025-08-27","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":59.25,"value":237000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":9130,"source":{"system":"sec-edgar","filing":"0001104659-25-085795","document":"tm2524772-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925085795/tm2524772-1_4seq1.xml","form_type":"4"}},{"id":1117492,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:24:13.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-25-016263","document":"form4-06092025_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000141588925016263/form4-06092025_080605.xml","form_type":"4"}},{"id":1196952,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-19T20:01:12.000Z","date":"2025-03-17","kind":"sale","planned":true,"acquired":false,"shares":4000,"price":54.25,"value":217000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":13130,"source":{"system":"sec-edgar","filing":"0001104659-25-025535","document":"tm259742-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925025535/tm259742-1_4seq1.xml","form_type":"4"}},{"id":1310234,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T23:11:34.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":6584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":6584,"derivative":{"exercise_price":38.98,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":6584},"source":{"system":"sec-edgar","filing":"0001104659-25-001435","document":"tm252003-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001435/tm252003-8_4seq1.xml","form_type":"4"}},{"id":1310233,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T23:11:34.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":5130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date."}],"balance_after":17130,"source":{"system":"sec-edgar","filing":"0001104659-25-001435","document":"tm252003-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925001435/tm252003-8_4seq1.xml","form_type":"4"}},{"id":1324792,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T23:05:06.000Z","date":"2024-12-18","kind":"grant","planned":false,"acquired":true,"shares":16733,"price":22.99,"value":384691.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date."}],"balance_after":57111,"source":{"system":"sec-edgar","filing":"0001628280-24-052271","document":"wk-form4_1734735898.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024052271/wk-form4_1734735898.xml","form_type":"4"}},{"id":1327427,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T23:19:12.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":3747,"price":22.04,"value":82583.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":40378,"source":{"system":"sec-edgar","filing":"0001628280-24-051925","document":"wk-form4_1734563946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024051925/wk-form4_1734563946.xml","form_type":"4"}},{"id":1327426,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T23:19:12.000Z","date":"2024-12-16","kind":"sale","planned":true,"acquired":false,"shares":3748,"price":21.9,"value":82081.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":44125,"source":{"system":"sec-edgar","filing":"0001628280-24-051925","document":"wk-form4_1734563946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024051925/wk-form4_1734563946.xml","form_type":"4"}},{"id":1408515,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-12T23:38:43.000Z","date":"2024-09-10","kind":"exercise","planned":true,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001104659-24-099420","document":"tm2423879-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924099420/tm2423879-1_4seq1.xml","form_type":"4"}},{"id":1408514,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T23:38:43.000Z","date":"2024-09-10","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":45,"value":360000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-099420","document":"tm2423879-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924099420/tm2423879-1_4seq1.xml","form_type":"4"}},{"id":1408513,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T23:38:43.000Z","date":"2024-09-10","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":12.88,"value":103040.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-24-099420","document":"tm2423879-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924099420/tm2423879-1_4seq1.xml","form_type":"4"}},{"id":1447998,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-26T20:31:18.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":8000,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001104659-24-083039","document":"tm2420254-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924083039/tm2420254-1_4seq1.xml","form_type":"4"}},{"id":1447997,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-26T20:31:18.000Z","date":"2024-07-24","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":40,"value":320000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-083039","document":"tm2420254-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924083039/tm2420254-1_4seq1.xml","form_type":"4"}},{"id":1447996,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-26T20:31:18.000Z","date":"2024-07-24","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":12.88,"value":103040.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-24-083039","document":"tm2420254-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924083039/tm2420254-1_4seq1.xml","form_type":"4"}},{"id":1462157,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-02T20:45:06.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":12770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":12770,"derivative":{"exercise_price":2.69,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":12770},"source":{"system":"sec-edgar","filing":"0001415889-24-018922","document":"form4-07022024_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553338/000141588924018922/form4-07022024_040701.xml","form_type":"4"}},{"id":1483284,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-11T20:30:48.000Z","date":"2024-06-07","kind":"exercise","planned":true,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options are fully vested."}],"balance_after":16000,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001104659-24-070420","document":"tm2416932-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924070420/tm2416932-2_4seq1.xml","form_type":"4"}},{"id":1483283,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:30:48.000Z","date":"2024-06-07","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":35,"value":280000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-070420","document":"tm2416932-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924070420/tm2416932-2_4seq1.xml","form_type":"4"}},{"id":1483282,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:30:48.000Z","date":"2024-06-07","kind":"exercise","planned":true,"acquired":true,"shares":8000,"price":12.88,"value":103040.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001104659-24-070420","document":"tm2416932-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924070420/tm2416932-2_4seq1.xml","form_type":"4"}},{"id":1486232,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T01:42:28.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":44000,"derivative":{"exercise_price":6.79,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001415889-24-016104","document":"form4-06082024_010625.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000141588924016104/form4-06082024_010625.xml","form_type":"4"}},{"id":1540977,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-16T21:38:22.000Z","date":"2024-04-15","kind":"grant","planned":false,"acquired":true,"shares":25540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Thirty three and thirty three one hundreds percent (33.33%) (and thirty three and thirty four one hundreds percent (33.34%) for year three) of the shares subject to the option will vest in three (3) annual installments commencing on the first anniversary of the date of grant such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date."}],"balance_after":25540,"derivative":{"exercise_price":2.81,"expiration_date":"2034-04-14","underlying":"Common Stock","underlying_shares":25540},"source":{"system":"sec-edgar","filing":"0001415889-24-010898","document":"form4-04162024_090416.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553338/000141588924010898/form4-04162024_090416.xml","form_type":"4"}},{"id":1606732,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-02T01:45:59.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":false,"shares":12975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.09,"expiration_date":"2026-07-16","underlying":"Common Stock","underlying_shares":12975},"source":{"system":"sec-edgar","filing":"0001104659-24-030157","document":"tm247765-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924030157/tm247765-2_4seq1.xml","form_type":"4"}},{"id":1606731,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-02T01:45:59.000Z","date":"2024-03-01","kind":"sale","planned":true,"acquired":false,"shares":12975,"price":31.34,"value":406636.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-030157","document":"tm247765-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924030157/tm247765-2_4seq1.xml","form_type":"4"}},{"id":1606730,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-02T01:45:59.000Z","date":"2024-03-01","kind":"exercise","planned":true,"acquired":true,"shares":12975,"price":6.09,"value":79017.75,"ownership":{"direct":true},"balance_after":24975,"source":{"system":"sec-edgar","filing":"0001104659-24-030157","document":"tm247765-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924030157/tm247765-2_4seq1.xml","form_type":"4"}},{"id":1679424,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-16T23:06:38.000Z","date":"2024-01-11","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":38.59,"value":50167.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $38.32 to $39.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":47870,"source":{"system":"sec-edgar","filing":"0001628280-24-001424","document":"wk-form4_1705446389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024001424/wk-form4_1705446389.xml","form_type":"4"}},{"id":1679423,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-16T23:06:38.000Z","date":"2024-01-11","kind":"sale","planned":true,"acquired":false,"shares":2634,"price":37.81,"value":99591.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Partial disposition of RSUs to satisfy tax withholding obligations."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions."}],"balance_after":49170,"source":{"system":"sec-edgar","filing":"0001628280-24-001424","document":"wk-form4_1705446389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024001424/wk-form4_1705446389.xml","form_type":"4"}},{"id":1687509,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T01:17:52.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":25700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":25700,"derivative":{"exercise_price":23.42,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":25700},"source":{"system":"sec-edgar","filing":"0001104659-24-001497","document":"tm241954-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924001497/tm241954-9_4seq1.xml","form_type":"4"}},{"id":1705867,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-19T20:41:34.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":14987,"price":25.41,"value":380819.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date."}],"balance_after":51804,"source":{"system":"sec-edgar","filing":"0001628280-23-041960","document":"wk-form4_1703018485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023041960/wk-form4_1703018485.xml","form_type":"4"}},{"id":1858404,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:45:47.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":2.88,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001610717-23-000141","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000161071723000141/form4.xml","form_type":"4"}},{"id":2052261,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-19T01:07:29.000Z","date":"2023-01-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 12 equal monthly installments following the date of grant."}],"balance_after":30000,"derivative":{"exercise_price":12.17,"expiration_date":"2033-01-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-004735","document":"tm233829-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923004735/tm233829-4_4seq1.xml","form_type":"4"}},{"id":2056908,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T01:23:17.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":4593,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents options, which will vest in one installment on the first anniversary of the grant date."}],"balance_after":4593,"derivative":{"exercise_price":33.03,"exercise_date":"2024-01-10","expiration_date":"2033-01-10","underlying":"Common Stock","underlying_shares":4593},"source":{"system":"sec-edgar","filing":"0001209191-23-003073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123003073/doc4.xml","form_type":"4"}},{"id":2056907,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T01:23:17.000Z","date":"2023-01-10","kind":"grant","acquired":true,"shares":7867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date."}],"balance_after":36817,"source":{"system":"sec-edgar","filing":"0001209191-23-003073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123003073/doc4.xml","form_type":"4"}},{"id":2056906,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-12T01:23:17.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":3200,"price":30,"value":96000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":28950,"source":{"system":"sec-edgar","filing":"0001209191-23-003073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919123003073/doc4.xml","form_type":"4"}},{"id":2233720,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T20:42:49.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":3.84,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001567619-22-012780","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000156761922012780/doc1.xml","form_type":"4"}},{"id":2253128,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-27T20:02:57.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date."}],"balance_after":20000,"derivative":{"exercise_price":8.31,"expiration_date":"2032-05-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-065869","document":"tm2214526-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922065869/tm2214526-8_4seq1.xml","form_type":"4"}},{"id":2282081,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-05T00:41:26.000Z","date":"2022-05-03","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option are vested in full."}],"balance_after":0,"derivative":{"exercise_price":8.59,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001104659-22-056000","document":"tm2214526-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922056000/tm2214526-1_4seq1.xml","form_type":"4"}},{"id":2282080,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-05T00:41:26.000Z","date":"2022-05-03","kind":"exercise","acquired":true,"shares":12000,"price":8.59,"value":103080.0,"ownership":{"direct":true},"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-22-056000","document":"tm2214526-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465922056000/tm2214526-1_4seq1.xml","form_type":"4"}},{"id":2440705,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-08T01:14:11.000Z","date":"2022-01-07","kind":"grant","acquired":true,"shares":6400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":32150,"source":{"system":"sec-edgar","filing":"0001209191-22-002597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122002597/doc4.xml","form_type":"4"}},{"id":2451962,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:35:24.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":272,"price":66.25,"value":18020.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":25750,"source":{"system":"sec-edgar","filing":"0001209191-22-001331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001331/doc4.xml","form_type":"4"}},{"id":2451961,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:35:24.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":2128,"price":65.01,"value":138341.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":26022,"source":{"system":"sec-edgar","filing":"0001209191-22-001331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001331/doc4.xml","form_type":"4"}},{"id":2451960,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T02:35:24.000Z","date":"2022-01-03","kind":"sale","acquired":false,"shares":2100,"price":64.23,"value":134883.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.71, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":28150,"source":{"system":"sec-edgar","filing":"0001209191-22-001331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919122001331/doc4.xml","form_type":"4"}},{"id":2601914,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-16T21:18:32.000Z","date":"2021-08-12","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from August 12, 2021 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":20000,"derivative":{"exercise_price":19.73,"expiration_date":"2031-08-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-21-015937","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1528115/000156761921015937/doc1.xml","form_type":"4"}},{"id":2691049,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T23:02:15.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":18000,"derivative":{"exercise_price":35.23,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-21-036670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919121036670/doc4.xml","form_type":"4"}},{"id":2923319,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T23:01:45.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":3750,"price":76.08,"value":285300.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.86 to $76.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":30250,"source":{"system":"sec-edgar","filing":"0001209191-21-001481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121001481/doc4.xml","form_type":"4"}},{"id":2923318,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-05T23:01:45.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":34000,"source":{"system":"sec-edgar","filing":"0001209191-21-001481","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919121001481/doc4.xml","form_type":"4"}},{"id":2949234,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-11T23:16:59.000Z","date":"2020-12-10","kind":"sale","acquired":false,"shares":1800,"price":73.1,"value":131580.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-20-063035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120063035/doc4.xml","form_type":"4"}},{"id":2949233,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-11T23:16:59.000Z","date":"2020-12-10","kind":"sale","acquired":false,"shares":1200,"price":68.5,"value":82200.0,"ownership":{"direct":true},"balance_after":26800,"source":{"system":"sec-edgar","filing":"0001209191-20-063035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120063035/doc4.xml","form_type":"4"}},{"id":3130439,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-29T22:19:40.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":15000,"derivative":{"exercise_price":16.54,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-033031","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919120033031/doc4.xml","form_type":"4"}},{"id":3151606,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:45:26.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":26000,"price":36.54,"value":950040.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to\n$37.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead\nPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares\nsold at each separate price within the ranges set forth in this footnote of this Form 4."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001209191-20-028975","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120028975/doc4.xml","form_type":"4"}},{"id":3324931,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T23:06:29.000Z","date":"2020-01-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":54000,"source":{"system":"sec-edgar","filing":"0001209191-20-001359","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919120001359/doc4.xml","form_type":"4"}},{"id":3493949,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T22:33:46.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":11.8,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-036214","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919119036214/doc4.xml","form_type":"4"}},{"id":3697727,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-11T23:15:19.000Z","date":"2019-01-11","kind":"sale","acquired":false,"shares":8500,"price":14.77,"value":125545.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units."}],"balance_after":46500,"source":{"system":"sec-edgar","filing":"0001209191-19-003464","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919119003464/doc4.xml","form_type":"4"}},{"id":3710965,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-04T01:18:14.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001209191-19-001551","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919119001551/doc4.xml","form_type":"4"}},{"id":3896617,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-12T22:52:00.000Z","date":"2018-05-29","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":6.98,"expiration_date":"2028-05-28","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-037317","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919118037317/doc4.xml","form_type":"4"}},{"id":4114705,"issuer":{"id":3472,"kind":"organization","name":"ARROWHEAD PHARMACEUTICALS, INC."},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-04T00:46:43.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-18-001549","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/879407/000120919118001549/doc4.xml","form_type":"4"}},{"id":4302849,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-26T21:37:40.000Z","date":"2017-05-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest at the earlier on (i) May 25, 2018, or (ii) the date of the 2018 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan)."}],"balance_after":12000,"derivative":{"exercise_price":8.59,"expiration_date":"2027-05-25","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-035969","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919117035969/doc4.xml","form_type":"4"}},{"id":4537153,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CFO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2016-12-01T16:05:42.000Z","date":"2016-11-29","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter.  The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company."}],"balance_after":75000,"derivative":{"exercise_price":3.35,"expiration_date":"2026-11-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-16-034662","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924316034662/doc4.xml","form_type":"4"}},{"id":4590183,"issuer":{"id":113073,"kind":"organization","name":"Calithera Biosciences, Inc.","symbol":"CALA"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SR. VP & CFO"}}],"security":"Common Stock","published_at":"2016-10-03T21:41:23.000Z","date":"2016-09-29","kind":"other","acquired":false,"shares":17485,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares transferred to the reporting person's ex-spouse pursuant to a divorce decree. The securities owned by the ex-spouse are not beneficially owned by the reporting person."}],"balance_after":17485,"source":{"system":"sec-edgar","filing":"0000899243-16-030612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1496671/000089924316030612/doc4.xml","form_type":"4"}},{"id":4602491,"issuer":{"id":3552,"kind":"organization","name":"Protagonist Therapeutics, Inc","symbol":"PTGX"},"owners":[{"id":35357,"kind":"person","name":"Waddill William D.","position":1,"cik":"0001553338","reported_name":"Waddill William D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-09-15T20:27:36.000Z","date":"2016-09-13","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in equal monthly installments over a three-year period from the vesting commencement date of August 10, 2016."}],"balance_after":24000,"derivative":{"exercise_price":12.88,"expiration_date":"2026-09-13","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-16-141595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1377121/000120919116141595/doc4.xml","form_type":"4"}}]}